Haleon (HLN) Convertible Debt (2021 - 2022)
Haleon (HLN) posted Convertible Debt of -$12.9 billion for Q2 2022, down 5668.42% on a QoQ basis from -$223.8 million in Q4 2021.
Haleon (HLN) Convertible Debt (2021 - 2022) Analysis & Trends
Haleon's Convertible Debt history runs 2 years deep, the most recent figure standing at -$12.9 billion for Q2 2022.
- Quarterly Convertible Debt changed N/A year-over-year to -$12.9 billion in Q2 2022, while the trailing twelve-month figure through Jun 2022 was -$12.9 billion (changed N/A YoY) and the FY2021 annual result came in at -$228.4 million, changed N/A from the prior year.
- Convertible Debt was -$12.9 billion for Q2 2022 at Haleon, down from -$223.8 million in the prior quarter.
- Across five years, Convertible Debt topped out at -$223.8 million in Q4 2021 and bottomed at -$12.9 billion in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | -12.91 Bn |
| Dec 31, 2021 | -223.77 Mn |